---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-006116"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:39:03.041822+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Insmed reports FY2025 revenue $606M (+67% YoY); guides BRINSUPRI to at least $1B in FY2026

## Summary
- Full-year 2025 total revenues $606.4M (+67% YoY); ARIKAYCE $433.8M (+19%), BRINSUPRI $172.7M since Aug launch.
- Guides FY2026 BRINSUPRI revenue ≥$1B, ARIKAYCE $450-470M; net loss $1,276.8M ($6.42/share) vs $913.8M in 2024.
- Cash & equivalents ~$1.4B; plans to fund pipeline including ENCORE, CEDAR, TPIP Phase 3, and gene therapy programs.
- Director David W.J. McGirr will not stand for re-election at 2026 annual meeting, no disagreement with company.

## SEC filing metadata
- accession: 0001140361-26-006116
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/0001140361-26-006116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/ef20066055_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-006116
- JSON: https://secwatch.observer/filing/0001140361-26-006116.json
- Plain text: https://secwatch.observer/filing/0001140361-26-006116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.